{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:12:14Z","timestamp":1788527534622,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcjd.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:31:51Z","timestamp":1786750311000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["All-Trans Retinoic Acid in Rodent Models of Autoimmune Diabetes: Clinical Potential of Targeted Drug Delivery"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-2746","authenticated-orcid":false,"given":"Benjamin","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-9873","authenticated-orcid":false,"given":"Dominick L.","family":"Auci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jcjd.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8227(11)70014-6","article-title":"Insulin effects in muscle and adipose tissue","volume":"93","author":"Dimitriadis","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"E735","DOI":"10.1152\/ajpendo.00159.2005","article-title":"Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues","volume":"289","author":"Thrailkill","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12669\/pjms.302.4396","article-title":"Effects of insulin on placental, fetal and maternal outcomes in gestational diabetes mellitus","volume":"30","author":"Arshad","year":"2014","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110031","article-title":"Comorbid autoimmune diseases and burden of diabetes-related complications in patients with type 1 diabetes from a Mediterranean area","volume":"191","author":"Gimenez-Perez","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/dme.14216","article-title":"The cognitive and psychological effects of living with type 1 diabetes: A narrative review","volume":"37","author":"van Duinkerken","year":"2020","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112277","article-title":"Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International Diabetes Federation Atlas, 11th edition, and the T1D Index version 3.0","volume":"225","author":"Ogle","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.08.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2026.08.001_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcjd.2012.01.002","article-title":"Islet transplantation at the University of Alberta: Status update and review of progress over the last decade","volume":"36","author":"Senior","year":"2012","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2026.08.001_bib9","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.2337\/diacare.26.12.3288","article-title":"Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: The National Institutes of Health experience","volume":"26","author":"Hirshberg","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2213-8587(25)00423-1","article-title":"Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic \u03b2-cell function pretransplant","volume":"14","author":"Shi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00592-016-0847-z","article-title":"The state of the art of islet transplantation and cell therapy in type 1 diabetes","volume":"53","author":"Pellegrini","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib12","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","article-title":"Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcjd.2026.08.001_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.716625","article-title":"Immune protection of stem cell-derived islet cell therapy for treating diabetes","volume":"12","author":"Tahbaz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jcjd.2026.08.001_bib14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.stem.2023.04.002","article-title":"Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes","volume":"30","author":"Hogrebe","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcjd.2026.08.001_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.17925\/EE.2023.19.2.7","article-title":"Teplizumab in type 1 diabetes mellitus: An updated review","volume":"19","author":"Thakkar","year":"2023","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib18","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and \u03b2-cell function: Two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2026.08.001_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc22-0908","article-title":"Two-year follow-up from the T1GER study: Continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders","volume":"46","author":"Rigby","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2026.08.001_bib21","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41591-024-03115-2","article-title":"Ustekinumab for type 1 diabetes in adolescents: A multicenter, double-blind, randomized phase 2 trial","volume":"30","author":"Tatovic","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/bs.apha.2015.04.006","article-title":"Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer","volume":"74","author":"Stevison","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413345","article-title":"The role of ATRA, natural ligand of retinoic acid receptors, on EMT-related proteins in breast cancer: Minireview","volume":"22","author":"Bobal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1084\/jem.20071251","article-title":"Oral tolerance: Is it all retinoic acid?","volume":"204","author":"von Boehmer","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mam.2011.11.001","article-title":"Vitamin A and immune regulation: Role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance","volume":"33","author":"Cassani","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1096\/fj.14-256743","article-title":"Retinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and \u03b2-cell mass","volume":"29","author":"Brun","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.jcjd.2026.08.001_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molimm.2008.12.028","article-title":"Retinoids differentially regulate the progression of autoimmune diabetes in three preclinical models in mice","volume":"47","author":"Stosic-Grujicic","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/db08-1154","article-title":"All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells","volume":"58","author":"Van","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2026.08.001_bib29","article-title":"All-trans retinoic acid prevents the development of type 1 diabetes by affecting the levels of interferon gamma and interleukin 4 in streptozotocin-induced murine diabetes model","volume":"15","author":"Wang","year":"2016","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.jcjd.2026.08.001_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/fcp.12523","article-title":"All-trans retinoic acid improves pancreatic cell proliferation on induced type 1 diabetic rats","volume":"34","author":"Ram\u00edrez-Moreno","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00125-007-0886-7","article-title":"The mechanisms of alloxan- and streptozotocin-induced diabetes","volume":"51","author":"Lenzen","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2026.08.001_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1258\/la.2010.010090","article-title":"Single dose streptozotocin-induced diabetes: Considerations for study design in islet transplantation models","volume":"45","author":"Deeds","year":"2011","journal-title":"Lab Anim"},{"key":"10.1016\/j.jcjd.2026.08.001_bib33","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ijms22041516","article-title":"Resolvin D1 decreases severity of streptozotocin-induced type 1 diabetes mellitus by enhancing BDNF levels, reducing oxidative stress, and suppressing inflammation","volume":"22","author":"Bathina","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1735-5362.329921","article-title":"Chrysin ameliorates STZ-induced diabetes in rats: Possible impact of modulation of TLR4\/NF-\u03ba\u03b2 pathway","volume":"17","author":"Salama","year":"2022","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib35","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/13880209.2017.1315603","article-title":"Beneficial effects of tyrosol on altered glycoprotein components in streptozotocin-induced diabetic rats","volume":"55","author":"Chandramohan","year":"2017","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib36","first-page":"181","article-title":"Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic \u03b2 cell glucotoxicity","volume":"8","author":"Wu","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jcjd.2026.08.001_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-0716-0385-7_6","article-title":"Mouse models of autoimmune diabetes: The nonobese diabetic (NOD) mouse","volume":"2128","author":"Chen","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib38","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.7150\/ijms.86566","article-title":"Preclinical models for type 1 diabetes mellitus \u2013 A practical approach for research","volume":"20","author":"Peng","year":"2023","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib39","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcjd.2026.08.001_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.medici.2018.02.001","article-title":"Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies","volume":"53","author":"Ighodaro","year":"2017","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jcjd.2026.08.001_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jnutbio.2014.11.018","article-title":"All-trans retinoic acid prevents oxidative stress-induced loss of renal tight junction proteins in type-1 diabetic model","volume":"26","author":"Molina-Jijon","year":"2015","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.jcjd.2026.08.001_bib42","doi-asserted-by":"crossref","DOI":"10.1590\/s0102-865020200010000006","article-title":"Effects of ATRA on diabetic rats with renal ischemia-reperfusion injury","volume":"35","author":"Cheng","year":"2020","journal-title":"Acta Cir Bras"},{"key":"10.1016\/j.jcjd.2026.08.001_bib43","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3349\/ymj.2015.56.6.1597","article-title":"All-trans retinoic acid has a potential therapeutic role for diabetic nephropathy","volume":"56","author":"Kim","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jcjd.2026.08.001_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group AAML1331 trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/jnci\/85.12.993","article-title":"Variability in the oral bioavailability of all-trans-retinoic acid","volume":"85","author":"Adamson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcjd.2026.08.001_bib46","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1200\/JCO.1992.10.11.1666","article-title":"Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer","volume":"10","author":"Smith","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib47","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.1997.15.11.3330","article-title":"Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer","volume":"15","author":"Adamson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib48","series-title":"Anti-cancer drugs \u2013 nature, synthesis and cell","article-title":"SHetA2, a new cancer-preventive drug candidate","author":"Liu","year":"2016"},{"key":"10.1016\/j.jcjd.2026.08.001_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.156915","article-title":"All-trans retinoic acid-functionalized injectable hydrogel with immunomodulation, osteogenesis and antibacterial capability for periodontitis therapy","volume":"500","author":"Xiang","year":"2024","journal-title":"Chem Eng J"},{"key":"10.1016\/j.jcjd.2026.08.001_bib50","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/10428190290021678","article-title":"Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia","volume":"43","author":"Ozpolat","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcjd.2026.08.001_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.17480\/psk.2019.63.6.367","article-title":"Sustained release of all-trans retinoic acid from chitosan-coated poly(DL-lactide-co-glycolide) nanoparticles","volume":"63","author":"Chae","year":"2019","journal-title":"Yakhak Hoeji"},{"key":"10.1016\/j.jcjd.2026.08.001_bib52","first-page":"576","article-title":"Tripterine and all-trans retinoic acid (ATRA)-loaded lipid-polymer hybrid nanoparticles for synergistic anti-arthritic therapy against inflammatory arthritis","volume":"49","author":"Li","year":"2021","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib53","first-page":"4639","article-title":"Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jcjd.2026.08.001_bib54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF03218586","article-title":"All-trans retinoic acid release from surfactant-free nanoparticles of poly(DL-lactide-co-glycolide)","volume":"16","author":"Jeong","year":"2008","journal-title":"Macromol Res"},{"key":"10.1016\/j.jcjd.2026.08.001_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101647","article-title":"Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer","volume":"31","author":"J\u00fanior","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106734","article-title":"Microfluidics produced ATRA-loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models","volume":"196","author":"Bahlool","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jcjd.2026.08.001_bib57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ibd\/izab204","article-title":"Oral delivery of encapsulated all-trans retinoic acid ameliorates disease in rodent models of colitis","volume":"28","author":"Nicoletti","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jcjd.2026.08.001_bib58","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1158\/0008-5472.CAN-14-0918","article-title":"Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells","volume":"74","author":"Chung","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcjd.2026.08.001_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2191-219X-3-60","article-title":"Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT","volume":"3","author":"Padmanabhan","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.jcjd.2026.08.001_bib60","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","article-title":"TGF-\u03b2 regulation of T cells","volume":"41","author":"Chen","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172721","article-title":"Orally delivered all-trans-retinoic acid- and transforming growth factor-beta-loaded microparticles ameliorate type 1 diabetes in mice","volume":"864","author":"Koprivica","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcjd.2026.08.001_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2374-815X\/6\/3\/001126","article-title":"Anti-fibrotic potential of all trans retinoic acid in inflammatory bowel disease","volume":"6","author":"Auci","year":"2018","journal-title":"Gastroenterol Pancreatol Liver Disord"},{"key":"10.1016\/j.jcjd.2026.08.001_bib63","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126001589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126001589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:13:42Z","timestamp":1788524022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267126001589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S1499267126001589"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.08.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All-Trans Retinoic Acid in Rodent Models of Autoimmune Diabetes: Clinical Potential of Targeted Drug Delivery","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Diabetes Canada.","name":"copyright","label":"Copyright"}]}}